Inventor · disambiguated record
Maria Jesus Blanco-Pillado
Also filed as: BLANCO-PILLADO MARIA JESUS
23 granted patents·26 pending applications·131 citations·filing 2003–2025
95Inventor score
Top patents by PatentIndex Score
49 records- 0197US11643434B2Neuroactive steroids and compositions thereofSAGE THERAPEUTICS INC·Filed 2020·Granted May 9, 2023·9 cites·25 claims
- 0295US11634453B2Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disordersSAGE THERAPEUTICS INC·Filed 2019·Granted Apr 25, 2023·8 cites·46 claims
- 0390US11396525B2C17, C20, and C21 substituted neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2017·Granted Jul 26, 2022·8 cites·15 claims
- 0488US12410210B2Neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2024·Granted Sep 9, 2025·0 cites·23 claims
- 0588US12252509B2Neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2024·Granted Mar 18, 2025·0 cites·19 claims
- 0687US12264177B2Neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2024·Granted Apr 1, 2025·0 cites·39 claims
- 0786US11999765B2Neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2023·Granted Jun 4, 2024·0 cites·21 claims
- 0886US11970514B2Neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2023·Granted Apr 30, 2024·0 cites·20 claims
- 0986US11912738B2Neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2023·Granted Feb 27, 2024·0 cites·17 claims
- 1085US11718642B2Compositions and methods for treating CNS disordersSAGE THERAPEUTICS INC·Filed 2019·Granted Aug 8, 2023·1 cites·13 claims
- 1184US7396943B2Opioid receptor antagonistsLILLY CO ELI·Filed 2004·Granted Jul 8, 2008·22 cites·2 claims
- 1284US7381719B2Diaryl ethers as opioid receptor antagonistLILLY CO ELI·Filed 2003·Granted Jun 3, 2008·23 cites·10 claims
- 1384US2024279268A1Neuroactive steroids and compositions thereofSAGE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1483US8642768B2Dimethyl-benzoic acid compoundsLILLY CO ELI·Filed 2013·Granted Feb 4, 2014·7 cites·13 claims
- 1582US2025171492A1Compositions and methods for treating cns disordersSAGE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1681US7196100B2Opioid receptor antagonistsLILLY CO ELI·Filed 2004·Granted Mar 27, 2007·19 cites·3 claims
- 1780US12421275B2Compositions and methods for treating CNS disordersSAGE THERAPEUTICS INC·Filed 2023·Granted Sep 23, 2025·0 cites·28 claims
- 1880US8933098B2Dimethyl-benzoic acid compoundsLILLY CO ELI·Filed 2013·Granted Jan 13, 2015·5 cites·4 claims
- 1980US2025236639A1Neuroactive steroids and compositions thereofSAGE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2079US7291632B2Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonistsLILLY CO ELI·Filed 2004·Granted Nov 6, 2007·11 cites·12 claims
- 2178US7608629B2(Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonistsLILLY CO ELI·Filed 2004·Granted Oct 27, 2009·12 cites·8 claims
- 2278US2023250128A1Neuroactive steroids and compositions thereofSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2378US2025154194A1Neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2478US2025092084A1C7, c12, and c16 substituted neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2577US2025250296A1Neuroactive steroids and compositions thereofSAGE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2676US7803813B2Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonistsLILLY CO ELI·Filed 2007·Granted Sep 28, 2010·2 cites·6 claims
- 2774US2025136638A19(11)-unsaturated neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2871US11993628B2C7, C12, and C16 substituted neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2021·Granted May 28, 2024·0 cites·39 claims
- 2971US2024300996A1Compounds for treating cns disordersSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3070US2023322846A9Neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3169US2024376144A9Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disordersSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3268US10005721B2Dimethylbenzoic acid compoundsLILLY CO ELI·Filed 2014·Granted Jun 26, 2018·1 cites·7 claims
- 3367US2023116347A1C17, c20, and c21 substituted neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3467US2021363175A19(11)-unsaturated neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3565US2019233465A1C7, c12, and c16 substituted neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3664US2022315621A1Compositions and methods for treating cns disordersSAGE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3764US2023312522A1Cyp46a1 inhibitors and methods of use thereofSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3863US8088800B24-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesityBENESH DANA RAEPSILON·Filed 2005·Granted Jan 3, 2012·3 cites·2 claims
- 3958US7858646B2Potentiators of glutamate receptorsLILLY CO ELI·Filed 2005·Granted Dec 28, 2010·0 cites·23 claims
- 4058US2024368214A1Positive nmda-modulating compounds and methods of use thereofSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4157US2023085354A1Compositions and methods for treating cns disordersSAGE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4257US2023257415A1Compounds for treating cns disordersSAGE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4355US2023250129A1Neuroactive steroids and compositions thereofSAGE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4455US2022372067A13.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereofSAGE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4555US2024101592A1Compositions and methods for treating cns disordersSAGE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4653US2024239835A9Neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4752US2024417423A1Deuterated positive nmda-modulating compounds and methods of use thereofSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4851US2021101928A1Compositions and methods for treating cns disordersSAGE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4948US2011034511A1Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonistsLILLY CO ELI·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Maria Jesus Blanco-Pillado files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →